Translate page

Ravi Bhatia


Professor Ravi Bhatia
Director of the Stem Cell Program at the University of Alabama in Birmingham (USA)

Overview of significant biological aspects presented during the meeting, including:

  • 03:44 Pre-treatment biological characteristics determining response
    • A single-cell Atlas identifies pretreatment features of primary imatinib resistance in CML
  • 11:47 Novel approaches to targeting leukemia stem cells
    • Integrated high-throughput drug profiling and CRISPR screening identify novel pathway vulnerabilities of leukemic stem cells in CML
    • Discovery of an exceptionally potent PROTAC degrading native and mutant BCR-ABL1 oncoprotein in CML
  • 21:59 Metabolic vulnerabilities in leukemia stem cells
    • Metabolic adaptation to tyrosine kinase inhibition in chronic myelogenous leukemia stem cells
    • Targeting HIF-2α for the treatment of CML by affecting LSCs metabolism and the vascular microenvironment
  • 26:33 Questions and Answers

If you have any questions or comments to the speaker, please email